Clinical Study
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) — Curium, a world
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
SPRING, Texas, Nov. 08, 2024 (GLOBE NEWSWIRE) — Io Therapeu
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
First patient dosed in Phase 1/Phase 2 LION-CS101 trial of A
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
VANCOUVER, British Columbia, Nov. 05, 2024 (GLOBE NEWSWIRE)
Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease
With a unique world-first ability to perform laser atherecto
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-‘749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
Teva’s presentation of findings from six schizophrenia studi
Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak
Photo caption: Rwanda Minister of State for Health, Yvan But
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
ICoN-1 study presentation planned November 1 at NTM Symposiu
Avance Clinical CEO and Asia Director Sign MOUs with Key Clinical Trial Sites in Korea around 2024 KoNECT
WAKE FOREST, N.C. and ADELAIDE, Australia , Oct. 29, 2024 (G
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Presentations highlight key preclinical data that support in
AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024
Two oral presentations and nine poster presentations will hi
【時事評論】傾聽真民意 建高效團隊
2024環球選舉年最矚目一戰，美國總統大選結果終於揭盅，前總統特朗普大勝現任副總統賀錦麗，明年一月再入主白宮，出任美國總統。雖然很多關注人士及各國政要都有這一預感，甚至已作好一定準備，但當預感變成事實，相信仍感錯愕。毫無疑問，特朗普再次執政將為美國以至全世界的政治經濟帶來一波大改變，是福是禍？現階段難說得很，因特朗普是個難以預測的政治人物。惟可以肯定的是，任何大變化都會影響澳門，哪怕只間接關係，新屆特區政府有為此作準備嗎？
甄慶悅
【主編前言】又見新規劃
早前政府向城規會介紹新一份《青洲都市化整治計劃》，調整後的總用地面積維持23.8萬平方米，但新計劃提出將青洲山保育面積增大兩倍多，居住人口則由2.7萬人大幅調低至1.3萬人。增加綠化面積，減少居住人口數量，如按新計劃實施，整治後的青洲區居住環境自然會有質的飛躍。
Mandy Kuok